Advertisement
Home Blog Page 3046
The prevalence of driving under the influence of alcohol and illicit drugs has been quantified in a report published Dec. 28 by the Substance Abuse and Mental Health Services Administration.

Survey Shows Lower Rate of Impaired Driving in U.S. for 2014

0
In 2014, 11.1 percent drove under the influence of alcohol, 4.1 percent drove under influence of drugs
Among U.S. adults

Iron Deficiency Anemia Ups Risk of Hearing Loss in U.S. Adults

0
After adjustment for sex, adults with IDA have increased odds of SNHL, combined hearing loss
Female gender is an independent predictor of all-cause mortality after percutaneous coronary intervention

Female Gender Predictor of All-Cause Mortality After PCI

0
Female gender independently predicts mortality at 30 days and one year in two large data sets
Ustekinumab is tolerated for treatment of atopic dermatitis in certain patients

Ustekinumab Tolerated in Severe Atopic Dermatitis

0
Four of 10 patients show response to treatment, with one patient experiencing complete response
An increase in human papillomavirus (HPV) prevalence after renal transplantation may result from reactivation of latent HPV infections in women

Increase in HPV Prevalence Seen After Renal Transplant in Women

0
Post-transplant HPV may be reactivation of latent infection during immunosuppression
Chair yoga may produce sustained improvements in pain interference among older adults with lower extremity osteoarthritis

Chair Yoga Helps Older Adults Manage Osteoarthritis Pain

0
Benefits include lasting reduction in pain interference and short-term decreases in pain and fatigue
Treatment with autologous chimeric antigen receptor-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 is associated with tumor regression in recurrent multifocal glioblastoma

Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma

0
Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen
The oral selective inhibitor of MAPK kinase 1 and 2

Selumetinib Active in Children With Neurofibromatosis Type 1

0
Patients were able to receive selumetinib on long-term basis; maximum tolerated dose 25 mg/m²
D-dimer unit type should be clarified and laboratories interested in implementing age-adjusted D-dimer cut-offs should use only specific D-dimer assays that have been adequately assessed in clinical studies

Age-Adjusted Cut-Offs in D-Dimer Testing for PE Cause Concern

0
D-dimer unit type should be clarified; specific assays that have been adequately assessed should be used
For patients with acute heart failure who experience minimal weight loss or weight gain

Weight Gain Worsens Post-Discharge Prognosis in Acute HF

0
Increased odds of 30-day mortality or heart failure readmission with each kg increase in weight